Literature DB >> 28131654

Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers.

Meihua Lin1, Jian Liu2, Huili Zhou3, Minglan Wu4, Duo Lv5, Yujie Huang6, Yunliang Zheng7, Jianzhong Shentu8, Lihua Wu9.   

Abstract

The pharmacokinetics (PKs) of febuxostat varies among individuals, while the main causes are still unknown. We investigated whether the polymorphisms of UGT1A1 and UGT1A3 played an important role in the disposition of the drug after oral administration of febuxostat tablet in Chinese subjects. A total of 42 healthy subjects were from two previous independent clinical bioequivalence (BE) trials of febuxostat, in which the same reference formulation (ULORIC® tablet, 80 mg) was taken, and thus the PK data were combined for the evaluation of pharmacogenomic effect on febuxostat PKs. Our study clearly indicated that the area under the plasma concentration-time curve (AUC) in the heterozygote and homozygote of UGT1A1*6 (c.211G > A, rs4148323) was significantly higher than that in the wild-type. Meanwhile, the clearance (CL/F) exhibited a significant reduction by 22.2%. Interestingly, UGT1A1*28, in perfect linkage disequilibrium (LD) with UGT1A3*2a, significantly increased its clearance. These results indicate that UGT1A1*6 was an important factor influencing the drug disposition, thus providing a probable explanation for interindividual variation of febuxostat PKs in Chinese subjects. In addition, by considering of the different allele distribution of UGT1A1*6 and *28 in Eastern and Western populations, these findings might further interpret the ethnic difference of febuxostat PKs.
Copyright © 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Febuxostat; Pharmacokinetics; Polymorphisms; UGT1A1; UGT1A3

Mesh:

Substances:

Year:  2016        PMID: 28131654     DOI: 10.1016/j.dmpk.2016.08.003

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  6 in total

Review 1.  Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Authors:  Garry G Graham; Sophie L Stocker; Diluk R W Kannangara; Richard O Day
Journal:  Curr Rheumatol Rep       Date:  2018-06-21       Impact factor: 4.592

2.  Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.

Authors:  Päivi Hirvensalo; Aleksi Tornio; Mikko Neuvonen; Tuija Tapaninen; Maria Paile-Hyvärinen; Vesa Kärjä; Ville T Männistö; Jussi Pihlajamäki; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875

3.  Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects.

Authors:  Yun Kim; Sangwon Lee; Yohan Kim; In-Jin Jang; SeungHwan Lee
Journal:  Clin Transl Sci       Date:  2021-10-19       Impact factor: 4.689

4.  Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

Authors:  Dinko Rekić; Susanne Johansson; Jacob Leander
Journal:  Clin Pharmacokinet       Date:  2020-09-19       Impact factor: 6.447

5.  Yinchenhao Decoction Ameliorates Alpha-Naphthylisothiocyanate Induced Intrahepatic Cholestasis in Rats by Regulating Phase II Metabolic Enzymes and Transporters.

Authors:  Ya-Xiong Yi; Yue Ding; Yong Zhang; Ning-Hui Ma; Feng Shi; Ping Kang; Zhen-Zhen Cai; Tong Zhang
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

6.  The correlation between UDP-glucuronosyltransferase polymorphisms and environmental endocrine disruptors levels in polycystic ovary syndrome patients.

Authors:  Yunyao Luo; Ying Nie; Lu Tang; Charles C Xu; Liangzhi Xu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.